Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.
Commentary|Articles|December 18, 2025
Experts Highlight SABCS 2025 Data With Potential to Shift Breast Cancer Practice
Author(s)Jax DiEugenio
Fact checked by: Ashling Wahner
Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.
Advertisement
Advertisement
The
Related to this article
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
An exploratory TROPION-Breast02 analysis showed CNS PFS and intracranial response benefits with datopotamab deruxtecan in TNBC with brain metastases.
Neoadjuvant T-DXd produced faster imaging responses vs ddAC in DESTINY-Breast11, but imaging poorly predicted pCR.
Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
Advertisement
Advertisement